Addition of liraglutide in patients with Type2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

Diabetic Medicine

Volumn 29, Issue 9, 2012, Pages 1115-1118

  Forst, T ^a   Michelson, G ^b   Ratter, F ^c   Weber, M M ^d   Anders, S ^e   Mitry, M ^a   Wilhelm, B ^c   Pfutzner A ^e  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Novo Nordisk Pharma GmbH   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e Clinical Research   (Germany)

Author keywords

Asymmetric dimethylarginin; Atherosclerosis; Endothelium; Glucagon like peptide1; Vascular

Indexed keywords

C REACTIVE PROTEIN; DIMETHYLARGININASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BODY WEIGHT; CAPILLARY FLOW; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG DOSE INCREASE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA CAPILLARY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; AGED; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICROCIRCULATION; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN; PROSPECTIVE STUDIES;

EID: 84865130603     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03589.x     Document Type: Article

References (12)

1. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide1 receptor are mediated through both glucagon-like peptide1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350.
2. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide1 on endothelium during the meal and evidence for an 'endothelial resistance' to glucagon-like peptide1 in diabetes. Diabetes Care 2011; 34: 697-702.
3. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293: E1289-E1295.
4. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000; 525: 263-270.
5. Courreges JP, Vilsboll T, Zdravkovic M, Le Thi T, Krarup T, Schmitz O et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type2 diabetes. Diabet Med 2008; 25: 1129-1131.
6. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Int J Obes Relat Metab Disord 2010; 53: 2256-2263.
7. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009; 201: 59-66.
8. Jia EZ, Yang ZJ, Zhu TB, Wang LS, Chen B, Cao KJ et al. Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis. Cardiology 2007; 110: 106-111.
9. Zethelius B, Lithell H, Hales CN, Berne C. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year-old men using the euglycaemic insulin clamp. Int J Obes Relat Metab Disord 2005; 48: 862-867.
10. Haffner SM, D'Agostino R, Mykkanen L, Hales CN, Savage PJ, Bergman RN et al. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. Stroke 1998; 29: 1498-1503.
11. Plutzky J, Garber AJ, Falahati A, Toft A. The once daily human GLP-1-analogue, liraglutide significantly reduces markers of cardiovascular risk in type2 diabetes: a meta-analysis of six clinical trials. Eur Heart J 2009; 30: S917-S919.
12. Pemp B, Garhofer G, Weigert G, Karl K, Resch H, Wolzt M et al. Reduced retinal vessel response to flicker stimulation but not to exogenous nitric oxide in type1 diabetes. Invest Ophthalmol Vis Sci 2009; 50: 4029-4032.